TRAILR Cancer Research Results

TRAILR, tumor necrosis factor-related apoptosis-inducing ligand receptor: Click to Expand ⟱
Source:
Type:
TRAILR refers to TRAIL receptors, which are part of the signaling pathway activated by TNF-related apoptosis-inducing ligand (TRAIL). There are several TRAIL receptors, primarily classified into two categories: death receptors and decoy receptors.
Types of TRAIL Receptors
Death Receptors:
TRAIL-R1 (also known as DR4): This receptor can initiate apoptosis when bound by TRAIL. It contains a death domain that activates downstream signaling pathways leading to cell death.
TRAIL-R2 (also known as DR5): Similar to TRAIL-R1, TRAIL-R2 can also trigger apoptosis upon TRAIL binding. It is often considered more potent in inducing apoptosis compared to TRAIL-R1.
Decoy Receptors:
TRAIL-R3 (also known as DcR1): This receptor does not contain a death domain and cannot initiate apoptosis. Instead, it acts as a decoy, binding TRAIL and preventing it from activating the death receptors.
TRAIL-R4 (also known as DcR2): Like TRAIL-R3, TRAIL-R4 also lacks a death domain and serves as a decoy receptor, inhibiting TRAIL-induced apoptosis.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
170- CUR,    Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
- vitro+vivo, Pca, PC3
TRAILR↑, BAX↑, P21↑, p27↑, NF-kB↓, cycD1/CCND1↓, VEGF↓, uPA↓, MMP2↓, MMP9↓, Bcl-2↓, Bcl-xL↓,
1644- HCAs,  PBG,    Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis
- in-vitro, Pca, LNCaP
NF-kB↓, TRAILR↑, Casp8↑, Casp3↑, MMP↓, Dose?,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   Casp8↑, 1,   p27↑, 1,   TRAILR↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,  

Migration ⓘ

MMP2↓, 1,   MMP9↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 2,  

Drug Metabolism & Resistance ⓘ

Dose?, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TRAILR, tumor necrosis factor-related apoptosis-inducing ligand receptor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:314  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page